FDA and EMA both hammer Brazilian sterile antibiotics maker over contamination concerns

Sterile manufacturing at Antibioticos Do Brasil plant in Sao Paulo.

A Brazilian antibiotics maker that was hammered in an FDA warning letter issued last month also caught the attention of the European Medicines Agency, which has banned its products because of concerns over the sterile manufacturing plant’s standards.

In fact, many of the issues noted by Italian inspectors during a December 12 inspection of the Antibioticos Do Brasil facility had been laid out in an FDA warning letter issued days before, the second for the Sao Paulo plant, which had also been cited in a 2009 FDA warning letter.

The FDA, which inspected the facility in April 2016, had noted that sterile areas didn’t have unidirectional airflow in sterile filling areas that could protect products from contamination. The agency also had concerns about other procedures to monitor for and protect aseptic filling areas from microbiological contamination. The agency recommended the company bring in experts to help it figure out how to meet standards.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Italian inspectors tallied four critical and seven major deficiencies at the plant, hammering the antibiotics maker for not keeping sterile manufacturing areas clean or safe from potential contamination.

Among the long list of problems inspectors noted was that plant employees in general didn’t seem to be trained or aware of GMP methods and there were few supervisors to oversee their work. They found the quality management system weak, data collection poor and “anomalous events had not been appropriately investigated and documented.”

The inspectors also noted that the company did not have any training on the differences in requirements for products being shipped into the EU versus the standards in Brazil.

Besides banning Antibioticos Do Brazil from shipping sterile drugs into the EU, the European Medicines Agency has suspended its certificate of manufacturing for sterile production. It said the facility would have to go through another inspection, showing the deficiencies had been corrected, to regain its status in the EU.

Suggested Articles

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.